IL17A and asthma: A study with humanized anti-IL-17 monoclonal antibody, secukinumab, in asthmatics (NCT01478360) was terminated requiring changes in study design and human anti-IL-17RA antibody brodalumab failed to show clinical efficacy in severe asthma [254].